492 related articles for article (PubMed ID: 25696911)
1. Chimeric antigen receptor T-cell therapy for ALL.
Maude SL; Shpall EJ; Grupp SA
Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):559-64. PubMed ID: 25696911
[TBL] [Abstract][Full Text] [Related]
2. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
Singh N; Frey NV; Grupp SA; Maude SL
Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
[TBL] [Abstract][Full Text] [Related]
3. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.
Maude SL; Teachey DT; Porter DL; Grupp SA
Blood; 2015 Jun; 125(26):4017-23. PubMed ID: 25999455
[TBL] [Abstract][Full Text] [Related]
4. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
5. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.
Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H
J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660
[TBL] [Abstract][Full Text] [Related]
6. CD19 chimeric antigen receptor T cell therapy for the treatment of B cell lineage acute lymphoblastic leukemia.
Chen R; Song XT; Chen B
Discov Med; 2015 Oct; 20(110):185-90. PubMed ID: 26562471
[TBL] [Abstract][Full Text] [Related]
7. CAR T-cells merge into the fast lane of cancer care.
Frey NV; Porter DL
Am J Hematol; 2016 Jan; 91(1):146-50. PubMed ID: 26574400
[TBL] [Abstract][Full Text] [Related]
8. The what, when and how of CAR T cell therapy for ALL.
Frey N
Best Pract Res Clin Haematol; 2017 Sep; 30(3):275-281. PubMed ID: 29050700
[TBL] [Abstract][Full Text] [Related]
9. CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies.
Turtle CJ; Riddell SR; Maloney DG
Clin Pharmacol Ther; 2016 Sep; 100(3):252-8. PubMed ID: 27170467
[TBL] [Abstract][Full Text] [Related]
10. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.
Zhang T; Cao L; Xie J; Shi N; Zhang Z; Luo Z; Yue D; Zhang Z; Wang L; Han W; Xu Z; Chen H; Zhang Y
Oncotarget; 2015 Oct; 6(32):33961-71. PubMed ID: 26376680
[TBL] [Abstract][Full Text] [Related]
11. Future directions in chimeric antigen receptor T cell therapy.
Maude SL
Curr Opin Pediatr; 2017 Feb; 29(1):27-33. PubMed ID: 27841776
[TBL] [Abstract][Full Text] [Related]
12. CAR T-cell therapy effective in B acute lymphoblastic leukaemia.
Wang M
Lancet Oncol; 2017 Jun; 18(6):e314. PubMed ID: 28528746
[No Abstract] [Full Text] [Related]
13. Potent Anti-leukemia Activities of Chimeric Antigen Receptor-Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia.
Hu Y; Wu Z; Luo Y; Shi J; Yu J; Pu C; Liang Z; Wei G; Cui Q; Sun J; Jiang J; Xie J; Tan Y; Ni W; Tu J; Wang J; Jin A; Zhang H; Cai Z; Xiao L; Huang H
Clin Cancer Res; 2017 Jul; 23(13):3297-3306. PubMed ID: 28039267
[No Abstract] [Full Text] [Related]
14. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia.
DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ
J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of lymphoblastic leukemia with CD19-specific modified chimeric antigen receptor T cells].
Li HH; Zhu P; Wu XQ; Liu YF
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1753-6. PubMed ID: 25543510
[TBL] [Abstract][Full Text] [Related]
16. CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.
Pehlivan KC; Duncan BB; Lee DW
Curr Hematol Malig Rep; 2018 Oct; 13(5):396-406. PubMed ID: 30120708
[TBL] [Abstract][Full Text] [Related]
17. CAR-T cell therapy in paediatric acute lymphoblastic leukaemia - past, present and future.
Rogosic S; Ghorashian S
Br J Haematol; 2020 Nov; 191(4):617-626. PubMed ID: 33190266
[TBL] [Abstract][Full Text] [Related]
18. Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.
Luskin MR; DeAngelo DJ
Curr Hematol Malig Rep; 2017 Aug; 12(4):370-379. PubMed ID: 28656487
[TBL] [Abstract][Full Text] [Related]
19. Chimeric antigen receptor T cells for sustained remissions in leukemia.
Maude SL; Frey N; Shaw PA; Aplenc R; Barrett DM; Bunin NJ; Chew A; Gonzalez VE; Zheng Z; Lacey SF; Mahnke YD; Melenhorst JJ; Rheingold SR; Shen A; Teachey DT; Levine BL; June CH; Porter DL; Grupp SA
N Engl J Med; 2014 Oct; 371(16):1507-17. PubMed ID: 25317870
[TBL] [Abstract][Full Text] [Related]
20. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors.
Aldoss I; Bargou RC; Nagorsen D; Friberg GR; Baeuerle PA; Forman SJ
Leukemia; 2017 Apr; 31(4):777-787. PubMed ID: 28028314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
